NCT06185543Phase 2Terminated

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

Study sponsor: NeuroSense Therapeutics Ltd. · NRSN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-30Actual
Enrollment · participants8Actual
Source updated2026-04-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 20 participants (planned). After: 8 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Nov 2025. After: 30 Sep 2025.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source